APM
STOK icon

Avidity Partners Management’s Stoke Therapeutics STOK Stock Holding History

Avidity Partners Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-891,100
Closed -$11.4M – 100
2022
Q3 		$11.4M Buy
+891,100
New +$14.2M 0.23% 68

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Avidity Partners Management's STOK Position: Q4 2022 in Review

Avidity Partners Management sold out of Stoke Therapeutics (STOK) in Q4 2022, closing a stake of 891,100 shares — an estimated $11.4M sold.

Avidity Partners Management first reported a position in STOK in Q3 2022 and held it in 1 quarter. The position peaked at $11.4M in Q3 2022. 107 funds tracked by Wall St. Rank hold STOK as of Q4 2022.

  • Avidity Partners Management reported no remaining Stoke Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Avidity Partners Management sold 891,100 Stoke Therapeutics shares in Q4 2022, an estimated $11.4M.
  • Avidity Partners Management first reported a position in Stoke Therapeutics in Q3 2022 and held it in 1 quarter.
  • Avidity Partners Management's Stoke Therapeutics position peaked at $11.4M in Q3 2022.
  • 107 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2022.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.